No Data
No Data
艾美疫苗:2023年度報告
Le Méridien Vaccine (06660.HK) received 6,400 additional H shares by Zhou Yan, worth approximately HK$53,800
On April 19, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 19, Zhou Yan increased her H shares of $Aimei Vaccine (06660.HK) by $6,400 at an average price of HK$8.404 per share on April 15, worth about HK$53,800. After the increase in holdings, Zhou Yan's latest shareholding was 24.5812 million shares, with a good position ratio of 4.99%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and top administration of listed companies
Le Méridien Vaccine (06660.HK) Voluntary Announcement: Controlling Shareholder Continues to Further Increase H Shares
Gelonghui, April 18, 丨 Le Méridien Vaccine (06660.HK) announced that the company's board of directors received a notice from Zhou Yan (Chairman of the Board, Executive Director, CEO and controlling shareholder of the company). Zhou Yan continued to further increase the company's H shares through the open market from January 22, 2024 to April 18, 2024. From November 14, 2023 to April 18, 2024, Zhou Yan has continued to increase her H shares in the company through the open market with total capital of HK$10,420,212.00, and it is not ruled out that she will continue to increase her shares in due course. As of this announcement
R&D investment in the Le Méridien vaccine has been growing rapidly in recent years. In 2024, three major iteratively upgraded vaccines will be declared and launched
Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3%
Aim Vaccine (HKG:6660) submitted pre-applications for clinical trials for two vaccines on Thursday, according to two separate Hong Kong bourse filings on the same day. These include the quadrivalent i
Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3%
Aim Vaccine (HKG:6660) booked an attributable loss of 1.3 billion yuan in 2023, up 307.1% from 319.6 million yuan the prior year, according to a Thursday Hong Kong bourse filing. Loss per share for th
No Data